OSI Pharmaceutical Gets a Boost from Cancer Drug

By Jon "DRJ" Najarian

Lung Cancer Drug Advances

OSI Pharmaceutical (OSIP) and Roche subsidiary Genentech (DNA) announced that a pivotal Phase III study of Tarceva met a key secondary endpoint of extending overall survival in patients with advanced lung cancer who received the drug immediately after initial chemotherapy. A statistically significant improvement in overall survival was seen in this final analysis of the total patient population. OSIP and Genentech will present during the 13th World Conference on Lung Cancer to be held July 31 to Aug. 4 in San Francisco. OSIP closed at $28.44 Friday but is trading at $30.75 in the pre-market on our Heat Seeker system.

RINO Charges Into Nasdaq

RINO International moves from the OTC Bulletin Board to the Nasdaq Monday. Through its subsidiaries and controlled affiliates, the company manufactures and installs proprietary waste water treatment systems for iron and steel manufacturers in China. RINO is higher by 9 percent Monday morning.

(Chart courtesy of tradeMONSTER)